Clinical trials: Cardiovascular Condition
Hypoxic Ischemic Encephalopathy
Darbe Administration in Newborns Undergoing Cooling for Encephalopathy
Selective head cooling or whole body hypothermia has become the standard of care for neonatal hypoxia-ischemia encephalopathy (HIE).
- Trial name
- DANCE (NCT01471015)
- Testing
- Darbepoetin alfa
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Utah
Chronic Kidney Diseases, Inflammation
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial.
- Trial name
- RESCUE (NCT03926117)
- Testing
- Ziltivekimab
- Where
- 49 sites in United States
- Volunteers
- 264 people
- Sponsor
- Novo Nordisk A/S
Anemia, Cardiovascular Disease
Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery
Anemia which is a decreased blood count or lower than normal hemoglobin (hgb), is a major health problem for patients having heart surgery.
- Trial name
- APART (NCT02189889)
- Testing
- EPO, Feraheme
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- University of Texas Southwestern Medical Center
Tricuspid Regurgitation
Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER)
The goal of this study is to determine the short term safety (<30 days) and efficacy (6 months) of the heterotopic implantation of the Edwards-Sapien XT valve in the inferior vena cava for the treatment of severe tricuspid…
- Trial name
- HOVER (NCT02339974)
- Testing
- Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Henry Ford Health System
Coronary Artery Disease, Myocardial Ischemia
Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging
Not infrequently, a physician is faced with uncertainty regarding the ability of a patient to perform adequate exercise in the noninvasive evaluation of known or suspected coronary artery disease (CAD) by the use of radionuclide…
- Trial name
- NCT01021618
- Testing
- Regadenoson, Symptom-limited exercise
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Hartford Hospital
Tumors
Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours
The purpose of this study is to determine whether doses of 30 mg and 45 mg AZD2171 can be well tolerated without significant drug withdrawal when accompanied by a suitable hypertension management strategy or dose reduction.
- Trial name
- NCT00264004
- Testing
- AZD2171
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 119 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
Shockwave Coronary Lithoplasty® Study (Disrupt CAD II)
The objective of this post market study is to examine the safety and performance of the Shockwave Coronary Intravascular Lithotripsy System for the treatment of narrowed coronary arteries before the doctor places a stent.
- Trial name
- NCT03328949
- Testing
- IVL Coronary Lithotripsy System
- Where
- 15 sites in Belgium, Denmark and 7 more
- Volunteers
- 120 people
- Sponsor
- Shockwave Medical, Inc.
Peripheral Artery Disease
Framing Clinical Trial Enrollment for Patients With Peripheral Artery Disease
It is uncertain whether opt-out framing will increase participation in a clinical trial intended to promote physical activity in patients with peripheral artery disease (PAD).
- Trial name
- NCT04536038
- Testing
- Opt-out
- Where
- United States
- Volunteers
- 5,176 people
- Sponsor
- University of Pennsylvania
Raynaud Disease
Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon
The aim of the study is to investigate the efficacy and safety of EGb 761® in patients with the primary Raynaud phenomenon, with regards to the frequency, duration and severity of vasospastic attacks.
- Trial name
- NCT00251238
- Testing
- Ginkgo biloba extract EGb 761
- Where
- Netherlands
- Volunteers
- 41 people
- Sponsor
- VSM Geneesmiddelen b.v.
Stroke
1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
The objective of the study is to find out the 1-year clinical outcomes among Acute Ischaemic Stroke (AIS) patients who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of…
- Trial name
- NCT05395338
- Testing
- rt-PA
- Where
- China
- Volunteers
- 12,551 people
- Sponsor
- Boehringer Ingelheim
Intracranial Atherosclerosis
Post Market Surveillance Study of the Wingspan Stent System
The primary objective of this study is to evaluate the rate of stroke and/or death in patients treated with the Wingspan Stent System, according to the Indications for Use, within 72 hours post procedure.
- Trial name
- WEAVE (NCT02034058)
- Testing
- Wingspan Stent System
- Where
- 26 sites in United States
- Volunteers
- 152 people
- Sponsor
- Stryker Neurovascular
Variceal Bleeding, Cirrhosis
Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding
This study is performed to compare the efficacy of terlipressin, somatostatin, and octreotide in patients with variceal bleeding for the control of variceal bleeding in combination with endoscopic therapy.
- Trial name
- NCT00966355
- Testing
- Terlipressin, Somatostatin, Octreotide
- Where
- South Korea
- Volunteers
- 1,034 people
- Sponsor
- Korea University
Myocardial Infarction
Study of Access Site for Enhancing PCI in STEMI for Seniors (SAFE STEMI for Seniors)
Patients with partially blocked blood vessel(s) in their heart may need a medical procedure called "Percutaneous Coronary Intervention (PCI)" to open the narrowed blood vessel(s).
- Trial name
- NCT02939976
- Testing
- Single Vessel Disease, Multi-vessel Disease, Culprit Vessel Only, Multi-vessel Disease, Complete Revascularization
- Where
- United States
- Volunteers
- 427 people
- Sponsor
- David Kong, M.D.
Right Ventricular Dysfunction
TEE 3D RV Assessment for SAVR, Mini AVR, and TAVR
Three-dimensional echocardiography has become a gold standard to assess right ventricular (RV) function, and investigators plan to use 3D transesophageal echocardiography to assess RV function in 3 types of aortic valve…
- Trial name
- NCT05804240
- Testing
- 3D TEE RVEF
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Thomas Jefferson University
Hypertension
A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure
The initial 12 week portion of this 20 week study will examine the ability of a combination of olmesartan medoxomil and amlodipine to lower the blood pressure of patients with high blood pressure who have not had sufficient blood…
- Trial name
- BP CRUSH (NCT00791258)
- Testing
- amlodipine and olmesartan medoxomil tablets, hydrochlorothiazide tablets
- Where
- 72 sites in United States
- Volunteers
- 999 people
- Sponsor
- Daiichi Sankyo
Tachycardia, Diabetes Mellitus
Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator
The MADIT S-ICD trial was designed to evaluate if subjects with a prior myocardial infarction, diabetes mellitus and a relatively preserved ejection fraction of 36-50% will have a survival benefit from receiving a subcutaneous…
- Conditions
- Tachycardia, Diabetes Mellitus, Cardiovascular Disease
- Trial name
- MADIT S-ICD (NCT02787785)
- Testing
- Subcutaneous Implantable Cardioverter Defibrillator
- Where
- 49 sites in United States, Germany and 5 more
- Volunteers
- 40 people
- Sponsor
- Boston Scientific Corporation
Multiple Myeloma
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
Multiple myeloma (MM) is a common incurable blood cancer causing debilitating symptoms-bone pain, kidney failure, low blood counts and infection.
- Trial name
- NCT02331368
- Testing
- Autologous Stem Cell Transplant, Melphalan, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as melphalan, prednisone, and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00477750
- Testing
- lenalidomide, melphalan, prednisone
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Peripheral Artery Disease, Femoropopliteal Artery Occlusion
LEVANT 2 Safety Registry
The primary objective of the LEVANT 2 Extended Follow-up Post-Approval Study (PAS 1) is to evaluate the long-term performance of the Lutonix Drug Coated Balloon (DCB) versus Percutaneous Transluminal Balloon Angioplasty (PTA) in…
- Conditions
- Peripheral Artery Disease, Femoropopliteal Artery Occlusion, Femoropopliteal Stenosis
- Trial name
- NCT01790243
- Testing
- Lutonix Drug Coated Balloon, Standard PTA Balloon
- Where
- 8 sites in United States
- Volunteers
- 1,189 people
- Sponsor
- C. R. Bard
Cardiogenic Shock
Early Insertion of Axillary Impella® With VA ECMO
Veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) is used as a rescue strategy for patients in acute hemodynamic deterioration such as cardiogenic shock and cardiopulmonary arrest with severe pulmonary congestion.
- Trial name
- NCT04084015
- Testing
- Axillary Impella®
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.